Estamos no ar no ! Saiba mais

CapsoVision Inc

CV

Valor de mercado US$ 347 mi

6,53 USD

+0,08

1,24%

No fechamento Atualizado 16 de out. 16:00 EDT

1 dia

1,24%

5 dias

-0,15%

1 mês

9,02%

3 meses

2,19%

6 meses

20,93%

No acumulado do ano

-36,23%

1 ano

41,65%

5 anos

86,57%

10 anos

86,57%

Sobre: CapsoVision Inc is a commercial-stage medical technology enterprise that innovates, manufactures, and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal (GI) system. The company's core technology platform is an orally ingestible capsule including multiple cameras facilitating 360-degree imaging, light-emitting diodes for measurement, onboard memory storage, and battery life permitting recording and onboard storage of video images. CapsoVision's products consist of the on-market CapsoCam Plus, directed at the small intestines, and the in-development CapsoColon 3D, directed at the large intestines. Geographically, the company generates the majority of its revenue from the United States.

Funcionários: 99

Saúde Dispositivos médicos

Notícias

Positivo

Neutro

Negativo

Sentimento 3 meses

Positivo 0%

Neutro 100%

Negativo 0%

CapsoVision to Present at the 20th Annual LD Micro Main Event

SARATOGA, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that Johnny Wang, President and Chief Executive Officer, David Garcia, Senior Vice President of Finance, and Doug Atkinson, Senior Vice President of Global Sales, will present at the 20th Annual LD Micro Main Event, taking place October 19-21, 2026, at the Luxe Sunset Boulevard Hotel in Los Angeles, CA.

CapsoVision to Present at the 20th Annual LD Micro Main Event

CapsoVision Announces FDA Clearance of AI Highlights for CapsoCam Plus®

AI-assisted reading tool designed to aid physician review of small bowel capsule endoscopy studies performed due to suspected bleeding using the CapsoCam Plus® system AI-assisted reading tool designed to aid physician review of small bowel capsule endoscopy studies performed due to suspected bleeding using the CapsoCam Plus® system

CapsoVision Announces FDA Clearance of AI Highlights for CapsoCam Plus®

CapsoVision to Participate in Upcoming Investor Conferences

SARATOGA, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that Johnny Wang, President and Chief Executive Officer, David Garcia, Senior Vice President of Finance, and Doug Atkinson, Senior Vice President of Global Sales, plan to participate in the following upcoming investor conferences: H.C.

CapsoVision to Participate in Upcoming Investor Conferences

CapsoVision, Inc. (CV) Q2 2026 Earnings Call Transcript

CapsoVision, Inc. (CV) Q2 2026 Earnings Call Transcript

CapsoVision, Inc. (CV) Q2 2026 Earnings Call Transcript

CapsoVision Q2 Earnings Call Highlights

CapsoVision NASDAQ: CV reported second-quarter revenue growth as sales of its CapsoCam Plus capsule endoscopy system increased, while the company advanced its artificial intelligence software rollout and development programs for colon and upper gastrointestinal applications.

CapsoVision Q2 Earnings Call Highlights

CapsoVision Reports Second Quarter 2026 Financial Results

SARATOGA, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financial results and provided a business update for its second quarter ended June 30, 2026.

CapsoVision Reports Second Quarter 2026 Financial Results

CapsoVision® Announces International Launch of AI Highlights

AI-assisted review feature designed to support physician review of small bowel capsule endoscopy studies using the CapsoCam Plus® system AI-assisted review feature designed to support physician review of small bowel capsule endoscopy studies using the CapsoCam Plus® system

CapsoVision® Announces International Launch of AI Highlights

CapsoVision to Release Second Quarter 2026 Financial Results on August 13, 2026

SARATOGA, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that the Company will release second quarter 2026 financial results on Thursday, August 13, 2026, after the close of market.

CapsoVision to Release Second Quarter 2026 Financial Results on August 13, 2026

CapsoVision Appoints Gastroenterology Leader David S. Shields, M.D.

SARATOGA, Calif., July 02, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (Nasdaq: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, announced the appointment of David S.

CapsoVision Appoints Gastroenterology Leader David S. Shields, M.D.

CapsoVision Q1 Earnings Call Highlights

CapsoVision NASDAQ: CV reported steady first-quarter revenue and said it continues to advance artificial intelligence and capsule endoscopy programs aimed at expanding the use of its gastrointestinal imaging platform.

CapsoVision Q1 Earnings Call Highlights

Ver ranking de notícias

Gráficos de preços implementados com Lightweight Charts™